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OBJECTIVES The study investigated the potential role of eight candidate genes in the susceptibility to
idiopathic dilated cardiomyopathy (IDC).
BACKGROUND Idiopathic dilated cardiomyopathy has a familial origin in 20% to 25% of cases, and several
genetic loci have been identified in rare monogenic forms of the disease. These findings led
to the hypothesis that genetic factors might also be involved in sporadic forms of the disease.
In complex diseases that do not exhibit a clear pattern of familial aggregation, the candidate
gene approach is a strategy widely used to identify susceptibility genes. All genes coding for
proteins involved in biochemical or physiological abnormalities of cardiac function are
potential candidates for IDC.
METHODS We studied 433 patients with IDC and 401 gender- and age-matched controls. Polymor-
phisms investigated were the I/D polymorphism of the angiotensin I-converting enzyme
(ACE) gene, the T174M and M235T polymorphisms of the angiotensinogen (AGT) gene,
the A-153G and A139C polymorphisms of the angiotensin-II type 1 receptor (AGTR1)
gene, the T-344C polymorphism of the aldosterone synthase (CYP11B2) gene, the G-308A
polymorphism of the tumor necrosis factor-alpha (TNF) gene, the R25P polymorphism of
the transforming growth factor beta1 (TGFB1) gene, the G111/in23T polymorphism of the
endothelial nitric oxide synthase (NOS3) gene and the C-1563T polymorphism of the brain
natriuretic peptide (BNP) gene.
RESULTS None of the polymorphisms were significantly associated with the risk or the severity of the
disease.
CONCLUSIONS We did not find evidence for an involvement of any of the 10 investigated polymorphisms in
the susceptibility to IDC. (J Am Coll Cardiol 2000;35:29–35) © 1999 by the American
College of Cardiology
Dilated cardiomyopathy (DCM) is a myocardial disease
characterized by impaired systolic function and dilation of
the left or both ventricles (1). Despite recent advances in
medical and surgical therapies, it remains an important
cause of mortality and morbidity and is a leading indication
for heart transplantation. The etiology of DCM is idio-
pathic in about half the patients. Family studies using
echocardiography to identify individuals with presymptom-
atic disease revealed that 20% to 25% of idiopathic dilated
cardiomyopathy (IDC) had a familial origin, a proportion
that had been considerably underestimated previously (2,3).
This finding raised the hypothesis that gene defects might
play an important role in the disease pathogenesis. Indeed,
several genetic loci responsible for rare autosomal dominant
or X-linked forms of DCM have been subsequently local-
ized by linkage analysis in large pedigrees (review in [4]).
The recognition of familial DCM led to the notion that
even in sporadic cases, genetic factors might contribute to
the disease susceptibility. In complex diseases that do not
exhibit a clear pattern of familial aggregation, the candidate
gene approach, which tests the role of known genes selected
for their potential implication in the pathophysiological
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process, is a strategy widely used (5,6). In DCM, all genes
coding for proteins involved in biochemical or physiological
abnormalities of cardiac function are potential candidates.
The CARDIGENE study is a large case-control study
designed to identify genetic factors involved in the pre-
disposition to IDC. This article reports the results of an
investigation of eight candidate genes: the angiotensin
I-converting enzyme (ACE), the angiotensin-II type 1
receptor (AGTR1), the angiotensinogen (AGT), the aldo-
sterone synthase (CYP11B2), the tumor necrosis factor-
alpha (TNF), the transforming growth factor beta1
(TGFB1), the endothelial nitric oxide synthase (NOS3) and
the brain natriuretic peptide (BNP) genes.
METHODS
Ethics approval for the study was obtained from the relevant
committees, and each subject gave written informed consent
for the study.
Patients. Patients aged 18 to 65 years (n 5 433) were
recruited between 1994 and 1996 from 10 hospitals (see list
in Appendix). The diagnosis of IDC was based on impaired
left ventricular systolic function (ejection fraction #40% on
ventriculography, radionucleotide angiography or echocar-
diography) and left ventricular dilation (end-diastolic vol-
ume .140 ml/m2 on ventriculography or end-diastolic
diameter .34 mm/m2 on echocardiography), confirmed
over a six-month period. For transplanted patients, these
criteria had to be fulfilled before heart transplantation.
Coronary angiography had to be performed in all subjects
aged .35 years, and patients with $50% obstruction of one
or more coronary arteries were excluded. Patients with
myocardial infarction, sustained systemic arterial hyperten-
sion, insulin-dependent diabetes, intrinsic valvular disease,
congenital cardiopathy, documented myocarditis, specific
primary or secondary heart muscle disease were also ex-
cluded. All patients had to be born in France, and their
parents had to be born in France or neighboring countries.
The mean left ventricular ejection fraction was 23.3 6
7.6% (n 5 433), the mean end-diastolic volume was 194 6
37 ml/m2 on ventriculography (n 5 182) and the mean
end-diastolic diameter was 40.1 6 5.1 mm/m2 (n 5 371) on
echocardiography. The mean duration between diagnosis
and inclusion was 7.1 6 5.3 years. Of the 433 patients, 229
(52.9%) had heart transplantation. Family history of DCM,
defined as definite or possible cardiomyopathy, or sudden
death #35 years, in first- or second-degree relatives, was
reported in 25% of patients.
Controls. Controls (n 5 401) were randomly sampled
from the French population surveys carried out in Lille
(northern France), Strasbourg (eastern France) and Tou-
louse (southern France) within the framework of the WHO
MONICA (MONItoring in CArdiovascular diseases)
project (7). A stratification was used to match the approx-
imate age distributions in cases and controls (age at diag-
nosis in cases and current age in controls). Controls with
clinical history of cardiovascular disease or insulin-
dependent diabetes were excluded.
Genotyping. Genomic DNA was prepared from white
blood cells by phenol extraction. Polymorphisms investi-
gated were an insertion (I)/deletion (D) polymorphism in
intron 16 of the ACE gene (8); two nucleotide substitutions
resulting in amino acid changes at codons 174 (Thr/Met)
and 235 (Met/Thr) of the AGT gene (9); two nucleotide
substitutions A-153G and A139C (previously named
A11166C) in the AGTR1 gene (10); a nucleotide substi-
tution T-344C in the CYP11B2 gene (11); a nucleotide
substitution G-308A in the TNF gene (12); a nucleotide
substitution resulting in an amino acid change at codon 25
(Arg/Pro) of the TGFB1 gene (13); a G/T nucleotide
substitution in intron 23 of the NOS3 gene (14); and a
nucleotide substitution C-1563T in the BNP gene (unpub-
lished).
Statistical analysis. Data were analyzed using the SAS
statistical software (SAS Institute, Cary, North Carolina).
Allele frequencies were estimated by gene counting. Hardy-
Weinberg equilibrium was tested by chi-square analysis.
Genotype and allele frequencies were compared between
cases and controls by chi-square analysis. Genotypic odds
ratios (OR) for disease, assuming a dominant or a recessive
model, were computed. Association between polymor-
phisms and case/control status was also tested by means of
logistic regression analysis controlling for age, gender
(matching criteria) and different covariates. A p value ,0.05
was considered statistically significant.
RESULTS
Characteristics of cases and controls are presented in Table
1. The mean age at diagnosis was 44.6 years in male and
48.4 years in female cases. Compared to controls, cases were
shorter by approximately 1 cm (p , 0.05), had a higher
alcohol and tobacco consumption (p , 0.001) and a higher
prevalence of non–insulin-dependent diabetes mellitus (p ,
0.05). Transplanted patients were younger, leaner and had a
lower alcohol consumption than did nontransplanted pa-
tients, and they were characterized by a more severe left
Abbreviations and Acronyms
ACE 5 angiotensin I-converting enzyme
AGT 5 angiotensinogen
AGTR1 5 angiotensin-II type 1 receptor
BNP 5 brain natriuretic peptide
CYP11B2 5 aldosterone synthase
DCM 5 dilated cardiomyopathy
IDC 5 idiopathic dilated cardiomyopathy
NOS3 5 endothelial nitric oxide synthase
TGFB1 5 transforming growth factor beta1
TNF 5 tumor necrosis factor-alpha
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ventricular dysfunction and a lower ejection fraction (data
not shown).
There was no deviation from Hardy-Weinberg equilib-
rium for any of the polymorphisms considered. None of the
polymorphisms exhibited significant difference of genotype
or allele frequencies between cases and controls (Table 2).
No significant association was observed when considering
either a dominant or a recessive model for each polymor-
phism (Fig. 1). We further investigated whether polymor-
phisms were associated with the severity of disease assessed
by ejection fraction (,/$24%), left ventricular dilation
(end-diastolic diameter ,/$40 mm/m2) or heart transplan-
Table 1. Characteristics of Cases and Controls











Age (yr)* 44.6 (0.5) 45.2 (0.5) 48.4 (1.0) 48.9 (1.1) 0.35
Height (cm) 173.1 (0.4) 174.3 (0.4) 161.7 (0.7) 162.2 (0.8) 0.02
Weight (kg) 76.6 (0.7) 77.6 (0.7) 60.3 (1.4) 62.8 (1.5) 0.15
BMI (kg/m2) 25.5 (0.2) 25.5 (0.2) 23.1 (0.4) 23.9 (0.5) 0.64
Alcohol (g/day) 78.1 (3.1) 26.7 (3.2) 9.0 (6.2) 12.2 (6.8) , 0.001
Smokers (%) 55.1 27.1 25.0 19.4 0.001
NIDDM (%) 4.4 1.5 4.6 2.8 0.03
*Age at diagnosis for cases and current age for controls. Data are expressed as mean (SE) or %.
BMI 5 body mass index (weight/height2); NIDDM 5 non–insulin-dependent diabetes mellitus.
Table 2. Genotype and Allele Frequencies of Candidate Gene Polymorphisms in Cases and Controls
Genotypes
Allele
Frequencyn (%) n (%) n (%)
ACE I/D II ID DD f (D)
Cases 94 (22.3) 200 (47.4) 128 (30.3) 0.54
Controls 71 (18.4) 190 (49.1) 126 (32.6) 0.57
AGT T174M TT TM MM f (M)
Cases 333 (77.8) 88 (20.6) 7 (1.6) 0.12
Controls 295 (74.1) 93 (23.4) 10 (2.5) 0.14
AGT M235T MM MT TT f (T)
Cases 157 (36.7) 200 (46.7) 71 (16.6) 0.40
Controls 131 (32.9) 195 (49.0) 72 (18.1) 0.43
AGTR1 A-153G AA AG GG f (G)
Cases 296 (69.5) 121 (28.4) 9 (2.1) 0.16
Controls 267 (67.4) 111 (28.0) 18 (4.6) 0.19
AGTR1 A139C AA AC CC f (C)
Cases 223 (52.6) 161 (38.0) 40 (9.4) 0.28
Controls 209 (52.5) 152 (38.2) 37 (9.3) 0.28
CYP11B2 T-344C TT TC CC f (C)
Cases 132 (31.0) 219 (51.4) 75 (17.6) 0.43
Controls 114 (29.0) 195 (49.6) 84 (21.4) 0.46
TNF G-308A GG GA AA f (A)
Cases 322 (75.2) 100 (23.4) 6 (1.4) 0.13
Controls 288 (72.7) 95 (24.0) 13 (3.3) 0.15
TGFB1 R25P RR RP PP f (P)
Cases 360 (85.3) 58 (13.7) 4 (1.0) 0.08
Controls 344 (86.2) 52 (13.0) 3 (0.8) 0.07
NOS3 G111/in23T GG GT TT f (T)
Cases 186 (43.4) 189 (44.1) 54 (12.6) 0.35
Controls 177 (44.9) 169 (42.9) 48 (12.2) 0.34
BNP C-1563T CC CT TT f (T)
Cases 401 (95.3) 18 (4.3) 2 (0.5) 0.03
Controls 379 (95.7) 17 (4.3) 0 (0.0) 0.02
Note: No significant difference existed between cases and controls.
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tation. No significant difference was found between sub-
groups of disease severity. The genotype and allele frequen-
cies did not differ between patients with and without a
familial history of DCM. Because alcohol intake is a major
etiologic factor for DCM, we investigated whether alcohol
might modulate the effect of polymorphisms on the risk of
DCM, but we did not find any evidence for alcohol–
genotype interaction. Finally, for each polymorphism, we
performed multivariate logistic regression analysis control-
ling for age, gender, height, weight, diabetes, alcohol intake,
smoking status and genotype (assuming either a recessive or
a dominant model), but genotypic ORs were little modified
by adjustment and remained nonsignificant.
DISCUSSION
Selection of the candidate genes and of the polymorphisms
examined in the present study was based on pathophysio-
logical considerations and/or results previously reported in
published data.
Genes of the renin-angiotensin-aldosterone system. The
renin-angiotensin-aldosterone system may be involved in
the susceptibility to DCM because of its action on cellular
hypertrophy, cell proliferation and cardiac remodeling. The
major biologically active product of the renin-angiotensin
system is angiotensin II, which is liberated from AGT by
the sequential action of renin and ACE. In adult humans,
the effects of angiotensin II are mainly mediated by the
AGTR1, a G-protein-coupled receptor expressed by many
cell types, in particular cardiomyocytes. Each component of
this system constitutes then a candidate for DCM. The
ACE I/D polymorphism was the first genetic factor re-
ported to be associated with nonfamilial IDC (15). How-
ever, the association seemed mainly due to a unexpected low
frequency of the DD genotype in controls rather than to an
excess in cases, and this finding failed to be confirmed in
later studies (16–19). In contrast, the DD genotype was
found associated with poorer survival and reduced left
ventricular performance in idiopathic heart failure and IDC
(17,20).
Angiotensinogen (AGT) is the precursor of angiotensin-I
and its concentration is rate-limiting for the generation of
angiotensin-II. Ever since the initial finding of an associa-
tion between the M235T and T174M polymorphisms of
the AGT gene and essential hypertension (9), the implica-
tion of the AGT locus in the pathogenesis of hypertension
and the regulation of blood pressure has been confirmed in
a large number of studies. A possible involvement of these
two polymorphisms in the susceptibility to IDC was inves-
tigated in a Japanese study, which failed to detect any
association with the disease itself or its severity (19).
The AGTR1 has been shown to be selectively down-
regulated in failing left ventricle from patients with end-
stage heart failure due to IDC, suggesting that the failing
human heart is exposed to increased concentrations of
angiotensin-II (21). Genetic variation at the AGTR1 locus
might then influence susceptibility to cardiomyopathy or
progression of the disease, although this possibility has not
yet been examined. The selection of the two polymorphisms
investigated in the present study (A-153G and A139C)
was based on the fact that they had been previously
suggested to be involved in susceptibility to myocardial
infarction (10,22) and essential hypertension (23).
Aldosterone, whose production is regulated primarily by
the renin–angiotensin system, may have indirect effects on
cardiac structure and function through its role in blood
pressure regulation (24). In addition, aldosterone has direct
effects on the heart in animal studies, including induction of
myocardial hypertrophy and fibrosis (25,26). The CYP11B2
T-344C polymorphism, which is associated with plasma
Figure 1. Genotypic odds ratios for DCM and 95% confidence intervals, assuming a recessive (left) or dominant (right) genetic model.
For all polymorphisms, the major allele was taken as the reference allele, except for ACE I/D where I was the reference allele. For TGFB1
R25P and BNP C-1563T, the recessive model was not considered because of the low frequency of the minor allele.
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aldosterone levels (27), has been shown in a small study to
strongly affect left ventricular size and mass in young adults
free of clinical heart disease (28).
The TNF gene. The hypertrophic response to myocardial
failure may be considered as a generalized inflammatory
response (29). In this line of evidence, several proinflam-
matory cytokines have been shown to be increased in the
myocardium of subjects with heart failure, among which one
of the most important by its powerful biological effects is
TNF. Levels of this protein are elevated in the circulation of
patients with congestive heart failure (30–32) and an
increased expression has been observed in the failing human
heart (33–35). Moreover, in transgenic mice, a cardiac
overexpression of TNF produces heart failure and DCM
(36,37). All these findings concur to suggest that TNF may
be an important mediator of cardiac inflammation evolving
to DCM. The G-308A polymorphism was selected because
it had been shown to affect transcriptional activity (38).
The TGFB1 gene. The TGFB1 is another cytokine that
might play an important role in the immune modulation of
cardiac function. It is a known regulator of cardiac fibro-
blasts and myocyte function. Its release by activated macro-
phages stimulates cardiac fibrosis and influences cardiac
remodeling, contributing to impairment of myocardial con-
tractility (39,40). The nonsynonymous TGFB1 R25P poly-
morphism, which affects TGFB1 production in vitro (41),
has been found associated with several diseases, in particular
hypertension (13,42).
The NOS3 gene. Nitric oxide is a powerful vasoactive
molecule produced from L-arginine by three distinct nitric
oxide synthase enzymes. Two constitutively present en-
zymes are found in neuronal and endothelial cells, respec-
tively, and the third one is inducible in many cell types after
immunological or inflammatory stimuli. The endothelial
isoform NOS3 is also constitutively expressed in cardiac
myocytes (43). Enhanced basal production of nitric oxide
has been reported in patients with heart failure (44–46)
while increased activity of inducible nitric oxide synthase
has been found in cardiac tissue from patients with DCM
(34,47–49). An explanation for these findings might be that
an excessive production of nitric oxide in cardiomyocytes,
when exerted over long periods, might lead to a depression
of myocardial contractility, an important feature of DCM.
A family study recently demonstrated genetic linkage be-
tween the level of plasma metabolites of nitric oxide and
markers located in the region of the NOS3 gene (50). This
result suggests that sequence variation in the NOS3 gene
might influence nitric oxide production, and thereby affect
the risk and/or the progression of DCM.
The BNP gene. Brain natriuretic peptide is mainly pro-
duced by the ventricles (51) and its secretion has been found
increased in the failing heart in proportion to the severity of
left-ventricular dysfunction (52). Its expression has been
observed primarily in myocytes in the interstitial fibrous area
in DCM (53). Plasma levels of BNP are raised in patients
with heart failure (51,54–56), left-ventricular dysfunction
(57,58), DCM (59) and have a prognostic role in mortality
of patients with congestive heart failure (60).
Power of the study. The CARDIGENE study, including
more than 400 patients with DCM, is the largest study
conducted so far on this topic. Assuming an additive or a
dominant genetic model, the sample size provided a $80%
power to detect the effect of any polymorphism having a
frequency $0.1 and associated with an OR for disease $1.6.
Under a recessive model, polymorphisms with a frequency
$0.25 and associated with an OR $2 could be detected.
The power of the study was then adequate to detect
associations of modest magnitude. Moreover, patients were
selected on strict criteria of disease severity, and both
patients and controls had to fulfill conditions of ethnic
homogeneity. In control subjects, there was no difference of
allele frequencies among the three MONICA regions de-
spite their geographical distance (northern, eastern and
southern France), making unlikely a risk of stratification of
the population for the polymorphisms considered.
Several reasons might explain the negative results. The
first one is that the investigated genes, despite being strong
candidates a priori, do not play any significant role in the
pathogenesis of DCM. A second reason might be that the
polymorphisms selected in each gene were not appropriate
and that there exist other unmeasured polymorphisms of
these genes whose effect on disease could not be detected
through linkage disequilibrium with the polymorphisms
studied. However, this explanation is rather unlikely, given
the strong linkage disequilibrium generally observed within
candidate genes. A third explanation might be related to the
heterogeneity of patients with respect to progression of the
disease. In actuality, the sample included both new and old
patients, some of them being followed up for more than 10
years. If the same genetic factor contributed to both the
susceptibility to disease and its mortality, then mixing new
cases and long-term survivors might mask the genetic effect.
This question would have to be addressed in longitudinal
studies.
APPENDIX
CARDIGENE Project Management Group: M. Desnos, Ser-
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Salpeˆtrie`re, Paris; M. Komajda, Service de Cardiologie,
Groupe Hospitalier Pitie´-Salpeˆtrie`re, Paris; G. Roize`s,
INSERM U249, Montpellier; K. Schwartz, INSERM
U523, Paris; L. Tiret, INSERM U525, Paris, France.
CARDIGENE recruitment centers: CHU Ambroise Pare´,
Boulogne Billancourt (O. Dubourg); CHU Henri Mondor,
Cre´teil (F. Paillart); CHR de Lille (A. Millaire); Hoˆpital
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Touboul); CHR de Nancy (Y. Juillie`re); CHR de Nantes
(J-B. Bouhour, N. Chedru); CHU Pitie´-Salpeˆtrie`re, Paris
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